Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Ke, Weixia ^a   Liu, Li ^a   Zhang, Chi ^a   Ye, Xiaohua ^a   Gao, Yanhui ^a   Zhou, Shudong ^a   Yang, Yi ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; HEPATITIS B, CHRONIC; SAFETY;

ADENINE; ANTIVIRAL AGENTS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; ORGANOPHOSPHONATES; SAFETY;

EID: 84902577349     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098865     Document Type: Article

References (45)

1. Safioleas M, Lygidakis NJ, Manti C (2007) Hepatitis B today. Hepatogastroenterology 54: 545-8. (Pubitemid 46724727)
2. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97-107.
3. Ganem D, Prince AM (2004) Hepatitis B virus infection natural history and clinical consequences. N. Engl. J. Med 350: 1118-1129. (Pubitemid 38298992)
4. Liaw YF, Leung N, Kao JH (2008) For the chronic hepatitis B guideline workshop party of the Asian-Pacific Association For The Study Of The Liver. Asian-Pacific consensusstatement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2: 263-283.
5. Lok ASF, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50: 1-36.
6. European Association For The Study Of The Liver. (2009) Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50: 227-242.
7. Aggarwal R, Ghoshal UC, Naik SR (2002) Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl. Med. J. India 15: 320-7. (Pubitemid 36113659)
8. Ayoub SB, Keefe EB (2008) Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 28: 167-77.
9. Leung N, Peng CY, Hann HW (2009) Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 49: 72-9.
10. Tenney DJ, Rose RE (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49:1503-14.
11. Tenny DJ, Pokornowsky KA, Rose RE (2008) Entecavir at five years show long term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2: A88-9.
12. Heathcote EJ, Marcellin P, Buti M (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140:132-43.
13. Patterson SJ, George J, Strasser SI (2011) Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60: 247-54.
14. Gao L, Huy NT (2013) Tenofovir is more effective than Entecavir for achieving rapid viral suppression in HBeAg-Positive chronic hepatitis B patients with high HBV DNA levels. Gastroenterology 144: S-971.
15. Woo G, Tomlinson G, Nishikawa Y (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139: 1218-29.
16. Liaw YF, Sheen IS, Lee CM (2011) Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53: 62-72.
17. Sriprayoon T, Lueangarum S, Suwanwela C (2012) Efficacy and safety of Entecavir versus Tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Gastroenterology 1421: S695-S695.
18. Koklu S, Tuna Y, Taner M (2013) Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 11: 88-94.
19. Dogan UB, Kara B (2012) Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 23: 247-52.
20. Kurdas O, Guzelbulut F (2011) Comparison of the efficacy of Entecavir and Tenofovir in chronic hepatitis B patients with high viral load and/or high fibrosis scores at week 48 of therapy. Gastroenterology 140: S930-931.
21. Jayakumar R, Joshi YK, Singh S (2012) Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab physicians 4:10.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
23. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-48.
24. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-88. (Pubitemid 17189972)
25. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.
26. Langley DR, Walsh AW, Baldick CJ (2007) Inhibition of hepatitis B virus polymerase by entecavir. J Virol 81: 3992-4001. (Pubitemid 46586894)
27. Fung J, Lai CL, Seto WK (2011) Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 66: 2715-25.
28. Buti M, Morillas RM, Prieto M (2010) A viral load reduction . 3 log at 12 week of Entecavir treatment correlated with HBe seroconversion in HBeAg positive patients. Results from a real-life setting study. Hepatology 52: A409.
29. Lampertico P, Vigano M, Soffredini R (2011) Entecavir monotherapy for nucnaïve chronic hepatitis B patients from field practice: high efficacy and favorable safety profile over 3 year. Hepatology 54: A1436.
30. Carey I, Nguyen HL, Joe D (2011) Denovo antiviral therapy with nucleos(t)ide analogues in 'real-life' patients with chronic hepatitis B infection: comparison of virological response between lamivudine + adefovir, entecavir vs. tenofovir therapy. Hepatology 54: A1396.
31. Ridruejo E, Adrover R, Cocozzella D (2011) Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Prac 65: 866-70.
32. Lampertico P, Sffredini R, Vigano M (2011) 2 year effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice. Hepatology 54: A1433.
33. Lin CL, Kao JH (2011) The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 26: 123-30.
34. Fontana RJ (2009) Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49: S185-95.
35. Duarte-Rojo A, Heathcote EJ (2010) Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 3: 107-19.
36. Marcellin P, Buti M, Krastev Z (2010) Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis. Hepatology 52:145A.
37. Heathcote EJ, Marcellin P, Buti M (2010) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140: 132-143.
38. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593-608.
39. Van Bommel, de Man RA, Wedemeyer H (2010) Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51: 73-80.
40. Reijnders JG, Deterding K, Petersen J (2010) Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 52: 493-500.
41. Suzuki Y, Suzuki F, Kawamura Y (2009) Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 24: 429-35.
42. Karino Y, Toyota J, Kumada H (2010) Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 4: 414-22.
43. Tenney DJ, Pokornoski KA, Rose RE (2009) Entecavir maintain a high genetic barrier to HBV resistance through 6 years in naïve patients. J. Hepatol 50: S10
44. Sheng YJ, Liu JY, Tong SW (2011) Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J 8: 393.
45. Petersen J, Buti M (2012) Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Rev Gastroenterol Hepatol 6: 683-93.